Publication Name	World Journal of Gastroenterology
Manuscript ID	30911
Country	Japan

Received	2016-10-23 17:43
Peer-Review Started	2016-10-25 09:03
To Make the First Decision	2016-12-02 08:16
Return for Revision	2016-12-02 11:45
Revised	2016-12-05 22:25
Second Decision	2016-12-16 17:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-12-21 16:26
Articles in Press	2016-12-21 16:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-01-06 17:53
Publish the Manuscript Online	2017-02-26 18:20

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Hepatitis C infected patients need vitamin D3 supplementation in the era of direct acting antivirals treatment
Manuscript Source	Invited Manuscript
All Author List	Yasuteru Kondo
Funding Agency and Grant Number
Corresponding Author	Yasuteru Kondo, MD, PhD, Chief Director, Department of Hepatology, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba, Sendai City 980, Miyagi, Japan. yasuteru@ebony.plala.or.jp
Key Words	Vitamin D; Hepatitis C virus; Direct acting antivirals; Hepatocarcinogenesis; Immune response
Core Tip	Although several mechanisms for the favorable effects of vitamin D3 (VitD3) supplementation were reported, the total effect of VitD3 supplementation remains unclear. Recently, the main treatment of chronic hepatitis C should be direct acting antivirals (DAAs) without pegylated interferon (Peg-IFN). Peg-IFN is a strong immune-modulator. Therefore, an immuno-logical analysis should be carried out to understand the effect of VitD3 after treatment of DAAs without Peg-IFN. The induction of a favorable immune response by adding VitD3 might be able to suppress the hepa-tocarcinogenesis after achieving SVR, especially in children and elderly patients with severe fibrosis lacking sufficient amounts of VitD3.
Publish Date	2017-02-26 18:20
Citation	Kondo Y. Hepatitis C infected patients need vitamin D3 supplementation in the era of direct acting antivirals treatment. World J Gastroenterol 2017; 23(8): 1325-1327
URL	http://www.wjgnet.com/1007-9327/full/v23/i8/1325.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i8.1325

Full Article (PDF)	WJG-23-1325.pdf
Full Article (Word)	WJG-23-1325.doc
Manuscript File	30911-Review.docx
Answering Reviewers	30911-Answering reviewers.pdf
Audio Core Tip	30911-Audio core tip.wav
Conflict-of-Interest Disclosure Form	30911-Conflict-of-interest statement.pdf
Copyright License Agreement	30911-Copyright assignment.pdf
Peer-review Report	30911-Peer-review(s).pdf
Scientific Misconduct Check	30911-Scientific misconduct check.pdf
Scientific Editor Work List	30911-Scientific editor work list.pdf